Margaret M. Byrne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Margaret M. Byrne has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
C. Blair
Markey Cancer Center, Lexington, KY/US
1 shared publication- Dido Franceschi
Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL
1 shared publication - Eli Avisar
University of Miami Miller School of Medicine, Miami, FL
1 shared publication - Erin E. Talbert
Department of Health, Sport, and Human Physiology, University of Iowa, Iowa City, USA
1 shared publication - Feng Miao
Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL
1 shared publication - Gerald H. Clamon
University of Iowa Hospital and Clinics, Iowa City, IA
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (6) , e1005165
Precision oncology’s translation gap—Can molecular tumor boards bridge it?
Precision oncology is revolutionizing cancer care, but isn't reaching enough patients. Molecular tumor boards (MTBs) translate complex genomic data to more effectively inform personalized care, and a new meta-analysis shows they boost clinical outcomes. But how can we feasibly and equitably expand the use of MTBs?
- 30 June 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (6) , e1005165
Open AccessPrecision oncology’s translation gap—Can molecular tumor boards bridge it?
Precision oncology is revolutionizing cancer care, but isn't reaching enough patients. Molecular tumor boards (MTBs) translate complex genomic data to more effectively inform personalized care, and a new meta-analysis shows they boost clinical outcomes. But how can we feasibly and equitably expand the use of MTBs?
- Open Access
Inflammation as a Therapeutic Target in Cancer Cachexia
Cachexia is a common complication of cancer and is associated with poor quality of life and a decrease in survival. Many patients with cancer cachexia suffer from inflammation associated with elevated cytokines, such as interleukin-1beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor (TNF). Single-agent trials to treat cancer cachexia have not led to substantial benefit as the type of cytokine which is elevated has rarely been specified and targeted. Cachexia may also be multifactorial, involving inflammation, anorexia, catabolism, depression, and pain, and targeting the multiple causes will likely be necessary to achieve improvement in weight and appetite. A PUBMED search revealed over 3000 articles on cancer cachexia in the past ten years. We attempted to review any studies related to inflammation and cancer cachexia identified by Google Scholar and PUBMED and further search for articles listed in their references. The National Comprehensive Cancer Network (NCCN) guidelines do not provide any suggestion for managing cancer cachexia except a dietary consult. A more targeted approach to developing therapies for cancer cachexia might lead to more personalized and effective therapy.
Open AccessInflammation as a Therapeutic Target in Cancer Cachexia
Cachexia is a common complication of cancer and is associated with poor quality of life and a decrease in survival. Many patients with cancer cachexia suffer from inflammation associated with elevated cytokines, such as interleukin-1beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor (TNF). Single-agent trials to treat cancer cachexia have not led to substantial benefit as the type of cytokine which is elevated has rarely been specified and targeted. Cachexia may also be multifactorial, involving inflammation, anorexia, catabolism, depression, and pain, and targeting the multiple causes will likely be necessary to achieve improvement in weight and appetite. A PUBMED search revealed over 3000 articles on cancer cachexia in the past ten years. We attempted to review any studies related to inflammation and cancer cachexia identified by Google Scholar and PUBMED and further search for articles listed in their references. The National Comprehensive Cancer Network (NCCN) guidelines do not provide any suggestion for managing cancer cachexia except a dietary consult. A more targeted approach to developing therapies for cancer cachexia might lead to more personalized and effective therapy.
- 28 August 2021
- Published by Wiley in European Journal of Haematology
- Vol. 107 (6) , 650-657
Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors
Introduction: With the increased use of immune checkpoint inhibitors (ICI), it is essential to improve our understanding of immune‐related adverse events (irAE). To date, most studies describing irAE have been performed in clinical trial populations, which may not be an accurate description of irAE in real‐world populations. Also, identification of patients at increased risk of irAE is needed as early recognition may improve irAE outcomes.Methods: We performed a retrospective analysis of patients who received an ICI between January 2014 and October 2018 at a single institution (Tufts Medical Center). Each patient was followed for up to 12 months for the outcome of a physician‐reported irAE. Kaplan‐Meier curves were created for the time to development and resolution of initial irAE. A Cox proportional hazards model was created to evaluate whether the following variables were independent predictors of an initial irAE: age ≥65 years, female sex, non‐Caucasian race, radiation in previous 6 months, current smoking status, melanoma, and combination ICI (ipilimumab and nivolumab).Results: Of 131 patients followed, 57 patients (43.5%) developed at least one irAE at a median of 250 days (95% confidence interval (CI) 132 days‐not estimable). The most common irAE included dermatitis, thyroid dysfunction, and pneumonitis. Nearly two‐thirds of patients with an irAE had ICI therapy withdrawn, and nearly 60% had immunosuppression initiated. In multivariable analysis, we found a significant association between irAE development and age ≥65 years hazard ratio (HR) 1.80, 95% CI (1.03‐3.14) and current smoking status (HR 2.26, 95% CI 1.06‐4.82).Discussion: We detected a high rate of irAE and that irAE and subsequent management can be clinically burdensome in this patient population. While further studies are needed to validate these findings, this study provides insights into the magnitude, time course, management of, and possible predictors of irAE in a real‐world setting.
- 28 August 2021
- Published by Wiley in European Journal of Haematology
- Vol. 107 (6) , 650-657
Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors
Introduction: With the increased use of immune checkpoint inhibitors (ICI), it is essential to improve our understanding of immune‐related adverse events (irAE). To date, most studies describing irAE have been performed in clinical trial populations, which may not be an accurate description of irAE in real‐world populations. Also, identification of patients at increased risk of irAE is needed as early recognition may improve irAE outcomes.Methods: We performed a retrospective analysis of patients who received an ICI between January 2014 and October 2018 at a single institution (Tufts Medical Center). Each patient was followed for up to 12 months for the outcome of a physician‐reported irAE. Kaplan‐Meier curves were created for the time to development and resolution of initial irAE. A Cox proportional hazards model was created to evaluate whether the following variables were independent predictors of an initial irAE: age ≥65 years, female sex, non‐Caucasian race, radiation in previous 6 months, current smoking status, melanoma, and combination ICI (ipilimumab and nivolumab).Results: Of 131 patients followed, 57 patients (43.5%) developed at least one irAE at a median of 250 days (95% confidence interval (CI) 132 days‐not estimable). The most common irAE included dermatitis, thyroid dysfunction, and pneumonitis. Nearly two‐thirds of patients with an irAE had ICI therapy withdrawn, and nearly 60% had immunosuppression initiated. In multivariable analysis, we found a significant association between irAE development and age ≥65 years hazard ratio (HR) 1.80, 95% CI (1.03‐3.14) and current smoking status (HR 2.26, 95% CI 1.06‐4.82).Discussion: We detected a high rate of irAE and that irAE and subsequent management can be clinically burdensome in this patient population. While further studies are needed to validate these findings, this study provides insights into the magnitude, time course, management of, and possible predictors of irAE in a real‐world setting.
- 1 October 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (10) , S805-S806
P2.11-32 Project ACTS (Adherence to CT Screening): Developing Patient Engagement Tools to Support Lung Cancer Screening Adherence
- 1 October 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (10) , S805-S806
P2.11-32 Project ACTS (Adherence to CT Screening): Developing Patient Engagement Tools to Support Lung Cancer Screening Adherence
- Open Access
- 1 March 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 2271-2278
Selecting treatment options in refractory metastatic colorectal cancer
Survival of patients with metastatic colorectal cancer (mCRC) has significantly improved in the last decade. Survival gains are not driven by advances in first-line therapy but by incremental additional effects of subsequent treatment lines. To maximize outcomes, patients should receive all active agents. Identification of patient subgroups is increasing individualization of treatment. Novel oral agents, such as regorafenib and TAS-102, as well as promising immunotherapeutic agents have offered salvage treatment options for refractory mCRC. Although most therapeutic developments for mCRC in the chemorefractory setting focuses on new targets and/or more potent agents, reconsideration of established targets has gained importance with the growth of a rational pharmacogenomic approach to drug development, such as HER2. The authors describe treatment options for patients with refractory colon cancer following first- and second-line therapy.
- 1 March 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 2271-2278
Open AccessSelecting treatment options in refractory metastatic colorectal cancer
Survival of patients with metastatic colorectal cancer (mCRC) has significantly improved in the last decade. Survival gains are not driven by advances in first-line therapy but by incremental additional effects of subsequent treatment lines. To maximize outcomes, patients should receive all active agents. Identification of patient subgroups is increasing individualization of treatment. Novel oral agents, such as regorafenib and TAS-102, as well as promising immunotherapeutic agents have offered salvage treatment options for refractory mCRC. Although most therapeutic developments for mCRC in the chemorefractory setting focuses on new targets and/or more potent agents, reconsideration of established targets has gained importance with the growth of a rational pharmacogenomic approach to drug development, such as HER2. The authors describe treatment options for patients with refractory colon cancer following first- and second-line therapy.
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 1034
Predictors of surgery types after neoadjuvant therapy for advanced stage breast cancer.
1034 Background: Despite the established guidelines for breast cancer treatment, there is still variability in surgical treatment after neoadjuvant therapy among women with large breast tumors, leading to variability in the outcome. Our objective was to identify possible predictors of the type of surgical treatment; mastectomy versus breast conserving surgery (BCS) in women with T3/T4 breast cancer who received neoadjuvant therapy. Methods: Population-based Florida Cancer Registry and U.S. Census from 1996 to 2009 were linked to select women diagnosed with T3/T4 breast cancer who then received neoadjuvant therapy followed by BCS or mastectomy. A multivariable logistic regression model was used to identify significant predictors of type of surgery by including sociodemographic characteristics (race, ethnicity, socioeconomic status, age, marital status, urban/rural residency), tumor characteristics (ER/PR status, histology, grade, SEER stage, regional nodes positivity), treatment facilities (hospital volume...
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 1034
Predictors of surgery types after neoadjuvant therapy for advanced stage breast cancer.
1034 Background: Despite the established guidelines for breast cancer treatment, there is still variability in surgical treatment after neoadjuvant therapy among women with large breast tumors, leading to variability in the outcome. Our objective was to identify possible predictors of the type of surgical treatment; mastectomy versus breast conserving surgery (BCS) in women with T3/T4 breast cancer who received neoadjuvant therapy. Methods: Population-based Florida Cancer Registry and U.S. Census from 1996 to 2009 were linked to select women diagnosed with T3/T4 breast cancer who then received neoadjuvant therapy followed by BCS or mastectomy. A multivariable logistic regression model was used to identify significant predictors of type of surgery by including sociodemographic characteristics (race, ethnicity, socioeconomic status, age, marital status, urban/rural residency), tumor characteristics (ER/PR status, histology, grade, SEER stage, regional nodes positivity), treatment facilities (hospital volume...